APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Arthritis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Arthritis Drug Market Outlook and Growth Opportunities 2026

Report ID 173967390422 December 2025194 pages

Choose your research edition.

Industry ResearchArthritis Drug Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Arthritis Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Arthritis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Arthritis Drug Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Arthritis Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Arthritis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Arthritis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Arthritis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Arthritis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Arthritis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Arthritis Drug market include Celltrion, F. Hoffmann-La Roche, GSK, Pfizer, Eli Lilly, Novartis and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Arthritis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Arthritis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Arthritis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Arthritis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Arthritis Drug Segment by Company

Celltrion

F. Hoffmann-La Roche

GSK

Pfizer

Eli Lilly

Novartis

Johnson & Johnson

Arthritis Drug Segment by Type

Analgesics

Biological DMARDs

Corticosteroids

Synthetic DMARDs

NSAIDs

Arthritis Drug Segment by Application

Hospital Pharmacies

Drug Stores

Retail Pharmacies

E-Commerce

Arthritis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Arthritis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Arthritis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Arthritis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Arthritis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Arthritis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Arthritis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Arthritis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Arthritis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Arthritis Drug industry.

Chapter 3: Detailed analysis of Arthritis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Arthritis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Arthritis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Arthritis Drug Industry Trends Table 2. Arthritis Drug Industry Drivers Table 3. Arthritis Drug Industry Opportunities and Challenges Table 4. Arthritis Drug Industry Restraints Table 5. Global Arthritis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Arthritis Drug Revenue Share by Company (2021-2026) Table 7. Global Arthritis Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Arthritis Drug Sales Volume Share by Company (2021-2026) Table 9. Global Arthritis Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Arthritis Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Arthritis Drug Key Company Manufacturing Base & Headquarters Table 12. Global Arthritis Drug Company, Product Type & Application Table 13. Global Arthritis Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Arthritis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Analgesics Table 18. Significant Companies of Biological DMARDs Table 19. Significant Companies of Corticosteroids Table 20. Significant Companies of Synthetic DMARDs Table 21. Significant Companies of NSAIDs Table 22. Global Arthritis Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Arthritis Drug Sales Volume by Type (2021-2026) & (k units) Table 24. Global Arthritis Drug Sales Volume by Type (2027-2032) & (k units) Table 25. Global Arthritis Drug Sales Volume Share by Type (2021-2026) Table 26. Global Arthritis Drug Sales Volume Share by Type (2027-2032) Table 27. Global Arthritis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Arthritis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Arthritis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Arthritis Drug Sales Value Share by Type (2021-2026) Table 31. Global Arthritis Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Pharmacies Table 33. Significant Companies of Drug Stores Table 34. Significant Companies of Retail Pharmacies Table 35. Significant Companies of E-Commerce Table 36. Global Arthritis Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Arthritis Drug Sales Volume by Application (2021-2026) & (k units) Table 38. Global Arthritis Drug Sales Volume by Application (2027-2032) & (k units) Table 39. Global Arthritis Drug Sales Volume Share by Application (2021-2026) Table 40. Global Arthritis Drug Sales Volume Share by Application (2027-2032) Table 41. Global Arthritis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Arthritis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Arthritis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Arthritis Drug Sales Value Share by Application (2021-2026) Table 45. Global Arthritis Drug Sales Value Share by Application (2027-2032) Table 46. Global Arthritis Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Arthritis Drug Sales by Region (2021-2026) & (k units) Table 48. Global Arthritis Drug Sales Market Share by Region (2021-2026) Table 49. Global Arthritis Drug Sales by Region (2027-2032) & (k units) Table 50. Global Arthritis Drug Sales Market Share by Region (2027-2032) Table 51. Global Arthritis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Arthritis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Arthritis Drug Sales Value Share by Region (2021-2026) Table 54. Global Arthritis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Arthritis Drug Sales Value Share by Region (2027-2032) Table 56. Global Arthritis Drug Market Average Price (US$/unit) by Region (2021-2026) Table 57. Global Arthritis Drug Market Average Price (US$/unit) by Region (2027-2032) Table 58. Global Arthritis Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Global Arthritis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Arthritis Drug Sales by Country (2021-2026) & (k units) Table 61. Global Arthritis Drug Sales Market Share by Country (2021-2026) Table 62. Global Arthritis Drug Sales by Country (2027-2032) & (k units) Table 63. Global Arthritis Drug Sales Market Share by Country (2027-2032) Table 64. Global Arthritis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Arthritis Drug Sales Value Market Share by Country (2021-2026) Table 66. Global Arthritis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Arthritis Drug Sales Value Market Share by Country (2027-2032) Table 68. Celltrion Company Information Table 69. Celltrion Business Overview Table 70. Celltrion Arthritis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Celltrion Arthritis Drug Product Portfolio Table 72. Celltrion Recent Development Table 73. F. Hoffmann-La Roche Company Information Table 74. F. Hoffmann-La Roche Business Overview Table 75. F. Hoffmann-La Roche Arthritis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. F. Hoffmann-La Roche Arthritis Drug Product Portfolio Table 77. F. Hoffmann-La Roche Recent Development Table 78. GSK Company Information Table 79. GSK Business Overview Table 80. GSK Arthritis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. GSK Arthritis Drug Product Portfolio Table 82. GSK Recent Development Table 83. Pfizer Company Information Table 84. Pfizer Business Overview Table 85. Pfizer Arthritis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Pfizer Arthritis Drug Product Portfolio Table 87. Pfizer Recent Development Table 88. Eli Lilly Company Information Table 89. Eli Lilly Business Overview Table 90. Eli Lilly Arthritis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Eli Lilly Arthritis Drug Product Portfolio Table 92. Eli Lilly Recent Development Table 93. Novartis Company Information Table 94. Novartis Business Overview Table 95. Novartis Arthritis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Novartis Arthritis Drug Product Portfolio Table 97. Novartis Recent Development Table 98. Johnson & Johnson Company Information Table 99. Johnson & Johnson Business Overview Table 100. Johnson & Johnson Arthritis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Johnson & Johnson Arthritis Drug Product Portfolio Table 102. Johnson & Johnson Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. Arthritis Drug Distributors List Table 106. Arthritis Drug Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Arthritis Drug Product Image Figure 2. Global Arthritis Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Arthritis Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Arthritis Drug Sales (2021-2032) & (k units) Figure 5. Global Arthritis Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Arthritis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Analgesics Image Figure 10. Biological DMARDs Image Figure 11. Corticosteroids Image Figure 12. Synthetic DMARDs Image Figure 13. NSAIDs Image Figure 14. Global Arthritis Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Arthritis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Arthritis Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Arthritis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Arthritis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Arthritis Drug Sales Value Share by Type (2021-2032) Figure 20. Hospital Pharmacies Image Figure 21. Drug Stores Image Figure 22. Retail Pharmacies Image Figure 23. E-Commerce Image Figure 24. Global Arthritis Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Arthritis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Arthritis Drug Sales Volume Share by Application (2021-2032) Figure 27. Global Arthritis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Arthritis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Arthritis Drug Sales Value Share by Application (2021-2032) Figure 30. Global Arthritis Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 31. Global Arthritis Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Arthritis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Arthritis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Arthritis Drug Sales Value (2021-2032) & (US$ Million) Figure 35. North America Arthritis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Arthritis Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Arthritis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Arthritis Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Arthritis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Arthritis Drug Sales Value (2021-2032) & (US$ Million) Figure 41. South America Arthritis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Arthritis Drug Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Arthritis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Arthritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Arthritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Arthritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Arthritis Drug Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Arthritis Drug Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Analgesics
  • Biological DMARDs
  • Corticosteroids
  • Synthetic DMARDs
  • NSAIDs
Applications
  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce
Companies covered
  • Celltrion
  • F. Hoffmann-La Roche
  • GSK
  • Pfizer
  • Eli Lilly
  • Novartis
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Arthritis Drug Sales Value (2021-2032)
  4. 1.2.2 Global Arthritis Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Arthritis Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Arthritis Drug Market Dynamics
  1. 2.1 Arthritis Drug Industry Trends
  2. 2.2 Arthritis Drug Industry Drivers
  3. 2.3 Arthritis Drug Industry Opportunities and Challenges
  4. 2.4 Arthritis Drug Industry Restraints
3 Arthritis Drug Market by Company
  1. 3.1 Global Arthritis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Arthritis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Arthritis Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Arthritis Drug Average Price by Company (2021-2026)
  5. 3.5 Global Arthritis Drug Company Ranking (2024-2026)
  6. 3.6 Global Arthritis Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Arthritis Drug Company Product Type and Application
  8. 3.8 Global Arthritis Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Arthritis Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Arthritis Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Arthritis Drug Market by Type
  1. 4.1 Arthritis Drug Type Introduction
  2. 4.1.1 Analgesics
  3. 4.1.2 Biological DMARDs
  4. 4.1.3 Corticosteroids
  5. 4.1.4 Synthetic DMARDs
  6. 4.1.5 NSAIDs
  7. 4.2 Global Arthritis Drug Sales Volume by Type
  8. 4.2.1 Global Arthritis Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Arthritis Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Arthritis Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Arthritis Drug Sales Value by Type
  12. 4.3.1 Global Arthritis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Arthritis Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Arthritis Drug Sales Value Share by Type (2021-2032)
5 Arthritis Drug Market by Application
  1. 5.1 Arthritis Drug Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Drug Stores
  4. 5.1.3 Retail Pharmacies
  5. 5.1.4 E-Commerce
  6. 5.2 Global Arthritis Drug Sales Volume by Application
  7. 5.2.1 Global Arthritis Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Arthritis Drug Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Arthritis Drug Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Arthritis Drug Sales Value by Application
  11. 5.3.1 Global Arthritis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Arthritis Drug Sales Value by Application (2021-2032)
  13. 5.3.3 Global Arthritis Drug Sales Value Share by Application (2021-2032)
6 Arthritis Drug Regional Sales and Value Analysis
  1. 6.1 Global Arthritis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Arthritis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Arthritis Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Arthritis Drug Sales by Region (2027-2032)
  5. 6.3 Global Arthritis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Arthritis Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Arthritis Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Arthritis Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Arthritis Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Arthritis Drug Sales Value (2021-2032)
  12. 6.6.2 North America Arthritis Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Arthritis Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Arthritis Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Arthritis Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Arthritis Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Arthritis Drug Sales Value (2021-2032)
  21. 6.9.2 South America Arthritis Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Arthritis Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Arthritis Drug Sales Value Share by Country, 2025 VS 2032
7 Arthritis Drug Country-level Sales and Value Analysis
  1. 7.1 Global Arthritis Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Arthritis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Arthritis Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Arthritis Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Arthritis Drug Sales by Country (2027-2032)
  6. 7.4 Global Arthritis Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Arthritis Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Arthritis Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Arthritis Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Arthritis Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Arthritis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Arthritis Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Arthritis Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Arthritis Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Arthritis Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Arthritis Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Arthritis Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Arthritis Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Arthritis Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Arthritis Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Arthritis Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Arthritis Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Arthritis Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Arthritis Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Arthritis Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Arthritis Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Arthritis Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Arthritis Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Arthritis Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Arthritis Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Arthritis Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Arthritis Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Arthritis Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Arthritis Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Arthritis Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Arthritis Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Arthritis Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Arthritis Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Arthritis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Celltrion
  2. 8.1.1 Celltrion Company Information
  3. 8.1.2 Celltrion Business Overview
  4. 8.1.3 Celltrion Arthritis Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Celltrion Arthritis Drug Product Portfolio
  6. 8.1.5 Celltrion Recent Developments
  7. 8.2 F. Hoffmann-La Roche
  8. 8.2.1 F. Hoffmann-La Roche Company Information
  9. 8.2.2 F. Hoffmann-La Roche Business Overview
  10. 8.2.3 F. Hoffmann-La Roche Arthritis Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 F. Hoffmann-La Roche Arthritis Drug Product Portfolio
  12. 8.2.5 F. Hoffmann-La Roche Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK Arthritis Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GSK Arthritis Drug Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Arthritis Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Arthritis Drug Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Arthritis Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Arthritis Drug Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Arthritis Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Arthritis Drug Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Johnson & Johnson
  38. 8.7.1 Johnson & Johnson Company Information
  39. 8.7.2 Johnson & Johnson Business Overview
  40. 8.7.3 Johnson & Johnson Arthritis Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Johnson & Johnson Arthritis Drug Product Portfolio
  42. 8.7.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Arthritis Drug Value Chain Analysis
  2. 9.1.1 Arthritis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Arthritis Drug Sales Mode & Process
  6. 9.2 Arthritis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Arthritis Drug Distributors
  9. 9.2.3 Arthritis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst